Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS0GA6)

Drug Name

AMY-101 Drug Info

Synonyms

UNII-4Z4DFR9BX7; 4Z4DFR9BX7; 1427001-89-5 (free base); Compstatin 40; Compstatin analog peptide CP40; CHEMBL4297260; 1427001-89-5; L-Isoleucinamide, D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophyl-N-methylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N2-methyl-, cyclic (3->13)-disulfide; S3,S13-Cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)

Indication

Disease Entry	ICD 11	Status	REF
Gingivitis	DA0B	Phase 2	[1]

Cross-matching ID

PubChem CID: 131634231
CAS Number: CAS 1427001-89-5
TTD Drug ID: DMS0GA6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Complement C3 (CO3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegcetacoplan	DM4HQ52	Paroxysmal nocturnal haemoglobinuria	3A21.0	Approved	[3]
Imprime PGG	DMIUA3M	Non-hodgkin lymphoma	2B33.5	Phase 2/3	[4]
POT-4	DMH0LM2	Macular degeneration	9B78.3	Phase 2	[5]
NGM621	DM84DP5	Geographic atrophy	9B75	Phase 2	[6]
Cysteine Sulfenic Acid	DM4GZUJ	N. A.	N. A.	Investigative	[7]
Ac-I[CV(Bta)QDWGAHRC]T	DM5NMVP	Discovery agent	N.A.	Investigative	[8]
Ac-I[CVWQDWGWHRC]T-NH2	DMDIUK6	Discovery agent	N.A.	Investigative	[8]
Ac-ICVWQDWGAHRCT-NH2	DMPSI26	Discovery agent	N.A.	Investigative	[9]
Ac-I[CV(Bta)QDWGAHRC]T-NH2	DMFLA5T	Discovery agent	N.A.	Investigative	[8]
Ac-I[CV(Bpa)QDWGAHRC]T	DMDFKU3	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement C3 (CO3)	TTJGY7A	CO3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Amyndas.
2	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
3	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
4	National Cancer Institute Drug Dictionary (drug id 599816).
5	Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
6	Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 Mar;235:131-142.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
9	Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.